Vir retains a 50-50 profit split and co-promotion option in the U.S., while receiving tiered double-digit royalties on ex-U.S ...
Vir Biotechnology Inc. VIR shares are up during Tuesday’s premarket session following a significant strategic collaboration ...
Vir Biotechnology Inc. VIR reported better-than-expected fourth-quarter earnings, anounced a significant strategic ...
Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium entered ...
Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date - Dose-dependent anti-tumo ...
AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.
Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...
The company is raising approximately $5.9 million through a public offering, which will provide necessary funding for advancing its drug candidates through clinical and preclinical development.
Gilead Sciences Inc. agreed to buy US biotech Arcellx Inc. in a deal with an equity value of up to $7.8 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results